Oncolys To Join With Bristol-Myers To Develop HIV Drug Globally
This article was originally published in PharmAsia News
Executive Summary
Japan's Oncolys BioPharma said it has licensed to U.S.-based Bristol-Myers Squibb global rights to develop a festinavir-based HIV compound